L’Oréal Invests in Swiss Longevity Biotech Firm Timeline

Global beauty leader L’Oréal has made an investment in Timeline, a Swiss consumer health biotech company focused on longevity, through its venture capital fund Business Opportunities for L’Oréal Development (Bold). Timeline successfully secured $66 million in an oversubscribed Series D financing round, which included strategic contributions from L’Oréal and Nestlé.

The funding aims to propel Timeline into a prominent longevity consumer health brand by expanding its scientific endeavors, product categories, and market presence across the food, beauty, and health sectors.

Central to Timeline’s approach is its exclusive molecule called ‘Mitopure,’ supported by over 15 years of research. Clinically proven, Mitopure targets a crucial cellular longevity pathway by renewing and recycling mitochondria, the cellular powerhouses. Maintaining optimal mitochondrial function is vital for supporting cellular energy, benefiting muscle strength, cognition, immune resilience, skin vitality, and other health aspects, offering a holistic approach to enhancing healthspan.

Timeline incorporates the properties of Mitopure into dietary supplements and skincare products. Barbara Lavernos, Deputy Chief Executive Officer overseeing research, innovation, and technology at L’Oréal, commented, “Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.” L’Oréal has been actively exploring and anticipating the intersection of longevity and beauty for the past decade.